Skip to content

Jason Drew Smith, General Counsel at UroGen Pharma, sold URGN on Sep 8, 2026

Data as of Oct 16

▼ SELL$64.6K1,519 shares at $42.54Jason Drew Smith General CounselURGN UroGen Pharma Ltd.
Watch URGN
Traded
Sep 8, 2026
Disclosed
Sep 9, 2026
Filed
1 day after the trade

Form 4s are due within two business days.

Official filing (SEC Form 4) ↗

The price around the disclosure

Jason Drew Smith, General Counsel at UroGen Pharma, sold URGN on Sep 8, 2026TRADEDDISCLOSED
URGNSimilar stocks (XLV — its sector index fund), rebased to URGN's price on the disclosure day
URGN since disclosure
−23.2%
after the sale
Similar stocks (XLV) since disclosure
+6.1%
XLV — its sector index fund

Change in closing price from Sep 9, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.

Our take

None of our tested rules fired on this trade.

See every trade on URGN →